Filing Flows

Filing Flows › Bolt Biotherapeutics (BOLT) › Takeover & LBO

Is Bolt Biotherapeutics (BOLT) a takeover target?

A leveraged buyout does not work for Bolt Biotherapeutics on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-10-23): Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications.

Why a leveraged buyout does not fit

The buyout model needs Bolt Biotherapeutics' revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.

What a takeover could cost

Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.

Rumors and deal signals

Bolt Biotherapeutics' latest quarter

Bolt Biotherapeutics, Q2 2026: revenue $5K (-100% year over year), net loss $7.7M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.

Questions

Is Bolt Biotherapeutics being acquired?

The latest signal on file is from 2026-10-23: Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.

Could private equity buy Bolt Biotherapeutics?

A leveraged buyout does not work for Bolt Biotherapeutics on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.